Investors who lost money with shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) should contact the Shareholders Foundation in connection with Lawsuit

An investor, who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), filed a lawsuit over alleged violations of Federal Securities Laws by Rocket Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have certain options and for certain investors are short and strict deadlines running. Deadline: August 11, 2025. NASDAQ: RCKT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Cranbury, NJ based Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported that its Net Loss increased from $245.59 million in 2023 to $258.74 million in 2024.

On May 27, 2025, Rocket Pharmaceuticals, Inc. announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket Pharmaceuticals, Inc. stated that, while the patient was dosed in May, the decision to amend the protocol was made "several months" earlier. Despite this, Rocket Pharmaceuticals, Inc. made no attempt to alert investors or the public to the change until after the SAE occurred.

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) declined from $9.80 per share on February 27, 2025, to as low as $2.19 per share on May 27, 2025.

The plaintiff claims that between February 27, 2025, to May 26, 2025, the Defendants provided investors with material information concerning Rocket's Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease, that the Defendants' statements included, among other things, confidence in the drug's safety and efficacy, as well as the clinical trial's detailed protocol and Rocket's purported ability to meet the trial's endpoints as per the Company's ascribed timeline, and that the defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RPA501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders.

Those who purchased shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.